Surgery Partners (SGRY)
(Real Time Quote from BATS)
$27.73 USD
-1.32 (-4.54%)
Updated Jul 22, 2024 12:02 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
Price, Consensus and EPS Surprise
SGRY 27.73 -1.32(-4.54%)
Will SGRY be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SGRY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SGRY
SGRY vs. MEDP: Which Stock Is the Better Value Option?
Wall Street Analysts Think Surgery Partners (SGRY) Could Surge 57.53%: Read This Before Placing a Bet
SGRY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Teladoc (TDOC) Soars 6.7%: Is Further Upside Left in the Stock?
Surgery Partners (SGRY) Q1 Earnings and Revenues Beat Estimates
DocGo Inc. (DCGO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Other News for SGRY
Surgery Partners (SGRY) Poised for Upside: A Comprehensive Buy Rating Justification
What You Missed On Wall Street This Morning
Surgery Partners explores potential sale, Bloomberg reports
TD Cowen Sticks to Its Buy Rating for Surgery Partners (SGRY)
Surgery Partners said to be exploring options including a sale